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Summary and Key Points 
1. Breast cancer is the the most common non-skin cancer and the 
second leading cause of cancer death in women (after lung cancer). 
2. The most common breast cancer type is ductal carcinoma followed 
by lobular carcinoma. 
3. Risk factors include family history, breast density, nulliparity, 
prolonged hormonal exposure, radiation exposure, high alcohol 
consumption, sedentary lifestyle and aging. 
4. Early stage disease is usually asymptomatic. 
5. Breast cancer screening lowers the risk of dying from breast cancer. 
6. Treatment is multidisciplinary and requires close cooperation 
between surgeons, radiation oncologists, and medical oncologists. 
7. Breast preservation is an important goal of treatment for early stage 
disease. Trials have shown that survival is equal whether a patient 
chooses mastectomy or lumpectomy with radiation therapy to the 
breast. 
8. The multidisciplinary approach to therapy has improved breast 
cancer outcome so that most U.S. women are cured. 
9. Breast cancer occurs in males but is rare. 
 
Introduction and Etiology 
Breast cancer is the most common non-skin cancer in United States (US) 
women and the second highest cause of cancer deaths. In 2011 the 
American Cancer Society estimated the annual incidence of invasive 
breast cancer to be 230,480 (female) and 2,140 (male) with total deaths of 
39,520 (female) and 450 (male). An additional 57,650 women were 
diagnosed with carcinoma in situ of the breast. The lifetime risk of 
developing breast cancer for U.S. women is 1 in 9. The annual death rate 
has been declining steadily since 1990 which is attributed to both 
improved detection and improvements in treatment.1 With these 
improvements, the net effect is most US women with breast cancer will be 
cured of their disease. 
 
Male breast cancer is rare, accounting for 1% of all breast cancers. The 
etiology is obscure, but there is a familial association with male or female 
breast cancer. 1. 
 
Risk factors for developing breast cancer in females include: 
• Age over 50 
• Personal or family history of breast cancer 
• Nulliparity 
• First child after age 30 
• Early menarche 
• Increased time between menarche and first child 
• Exposure of the breasts to ionizing radiation before age 40  
• High alcohol consumption 
• Sedentary lifestyle 
• Excessive weight gain 
• Hormonal exposure 
• Breast density 
 
Overall, increased estrogen and progesterone exposure increases breast 
cancer risk. Smoking does not seem to be a risk factor. Breast cancer is 
more common in Caucasians, upper socioeconomic classes and people of 
Jewish descent. Germline mutations of BRCA1 or BRCA2 are present in 
5-10% of breast cancer patients. Genetic testing for BRCA1 and BRCA2 is 
available. A common method to determine a woman’s risk of developing 
breast cancer, the modified Gail model, is available at the US National 
Cancer Institute (NCI) web site. 
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Screening 
The mammographic findings of breast cancer are commonly a mass 
and/or suspicious calcifications. Mammography routinely includes 2 views 
of each breast:  cranio-caudal (CC) and medial-lateral oblique (MLO). The 
mammograms are labeled noting the side and the orientation by 
positioning the markers on the images closest to the axilla. At least 10% of 
tumors are not seen on mammography, particularly lobular carcinoma in 
situ (LCIS) and invasive lobular carcinoma. 
 
Early stage breast cancer is usually asymptomatic, making screening all 
the more important. Screening mammography for women between the 
ages of 50 and 70 has been shown to both shift diagnosis to an earlier 
stage and to reduce mortality. However, it is controversial whether the 
risks of mammography and its cost outweigh the reduction in mortality in 
women younger than 50. 
 
In 2009, the U.S. Preventative Services Task Force issued revised 
guidelines for mammographic screening that recommended against 
screening for women < 50 years old and > 75 years old, recommended 
against teaching breast self-examination and recommended only biennial 
screening. Many experts and groups (including the American Cancer 
Society (ACS), The American College of Surgeons, The American College 
of Obstetricians-Gynecologists and the American College of Radiologists) 
oppose these new guidelines. Therefore, despite the new Task Service 
recommendations, we think it is reasonable for patients of average risk to 
follow the ACS Guidelines' recommendation of yearly mammograms 
starting at age 40 and continuing in healthy women with a >10 year life 
expectancy. 
 
Pathology 
The most common form of breast cancer in women is ductal carcinoma of 
the usual type (Figure 1 a,b) followed by lobular cancer and less frequently 
by other histologic subtypes (i.e. special types of ductal carcinoma such as 
adenoid cystic, neuroendocrine, papillary, medullary etc.). Rarely 
lymphomas, sarcomas and metastasis may occur in the breast. Since 
male breast tissue does not contain lobules, ductal carcinoma is most 
common type in men. 
 
Figure 1 a,b. Mastectomy, Invasive Ductal Carcinoma. (a) The carcinoma has 
ulcerated the nipple. (b) The cross-section shows the skin with ulceration (adjacent 
to the ruler) by the cancer which is the solid white area with irregular infiltrating 
borders. The fatty breast parenchyma appears yellow and the surgical margin has 
been inked black by the pathologist. University of Massachusetts Medical School, 
Department of Pathology. 
 
As the name implies, ductal carcinoma arises from the terminal duct and is 
characterized by the formation of glands (Figure 2). 
 
Figure 2 a,b,c,d. Breast Invasive Ductal Carcinoma. (a) Poorly differentiated. 
Notice that it does not form glands and has no similarity to normal breast tissue. (b) 
Moderately differentiated with a mixture of glands and sheets of cells. (c) Well-
differentiated has well-formed glands which resemble normal. Note the cancer 
invasion of the adjacent fat, and atypical nuclear features noted on high 
magnification (d) 60x magnification. University of Massachusetts Medical School, 
Department of Pathology. 
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Breast ductal adenocarcinoma may be focal or multifocal. The precursor 
lesion is ductal carcinoma in situ (DCIS) and comprises 15-30% of breast 
cancers. DCIS can be classified into subtypes. The most common two 
include DCIS comedo type and noncomedo DCIS. The classic picture of 
DCIS comedo type is the presence of high grade pleomorphic nuclei 
contained within the basement membrane with central necrosis. This 
necrosis is referred to comedo necrosis. The necrotic cell membranes may 
calcify allowing screening mammography to detect these areas. Calcium, 
in itself, is not specific for cancer and can be found in benign proliferating 
glands. The more frequently encountered noncomedo DCIS includes solid, 
papillary, micropapillary and cribiform types (Figure 3 a, b, c, d). In these 
types the nuclei appear similar or clonal and can show low or high grade 
nuclear atypia. 
 
 
Figure 3 a,b,c,d. Ductal Carcinoma In Situ (DCIS) (10x). (a) Intraductal 
calcifications (purple crystalline material) which can be detected by screening 
mammography. (b) DCIS with a cribiform pattern with rigid “cookie cutter-like” 
punched out holes. (c) Cribiform DCIS with comedo necrosis. (d) Solid DCIS with 
comedo necrosis with high grade nuclear atypia. University of Massachusetts 
Medical School, Department of Pathology. 
 
 
In contrast, lobular carcinoma tends to be a diffuse process that can 
involve both breasts at the time of asymptomatic presentation. The 
histology is characterized by single cells classically seen in a single file 
line infiltrating into the breast parenchyma (Figure 4 a, b). They can also 
infiltrate in single file lines around benign residual normal ducts referred to 
as “targetoid pattern” (Figure 4 c, d). See Figure 2 for comparison with 
invasive ductal carcinoma and note lobular carcinoma lacks gland 
formation. 
 
 
Figure 4 a,b,c,d. Lobular Carcinoma. (a) The malignant cells lack any ductal 
formation, but instead line up in a row like a string of pearls (10x). Higher 
magnification (60x) shows each of the cells in the group are relatively small. (c) 
Targetoid pattern, low magnification (10x) (d) Targetoid pattern, higher 
magnification (40x). University of Massachusetts Medical School, Department of 
Pathology. 
 
The precursor lesion of lobular carcinoma in situ appears as monotonous 
clonal population with a well-circumscribed basement membrane. It often 
has the appearance of a bag of marbles with slight bulging of the borders 
and retains some semblance to lobular configuration (Figures 5 & 6). 
Unlike DCIS, LCIS does not require wide excision so the pathologic 
distinction is important. 
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Figure 5. Normal Breast Lobule (10x). University of Massachusetts Medical 
School, Department of Pathology. 
 
 
 
Figure 6. Lobular Carcinoma In Situ (10x). University of Massachusetts Medical 
School, Department of Pathology. 
 
Work-up and Staging 
The work-up for early stage breast cancer includes history and physical, 
basic labs (cbc, chemistry profile to include liver function tests), and biopsy 
for histological and hormonal evaluation. In taking the history, it is 
important to ask menstrual status, parity and family history. Clinical 
examination of the axilla can be misleading with about 30% false positive 
and 30% false negative results. 
 
For invasive cancer, it is important to surgically stage the axilla with either 
sentinel lymph node sampling or an axillary lymph node dissection. For 
stage I and II patients, bone scan is not necessary (only 2% yield); for 
stage III, bone scan is indicated as asymptomatic metastases can be 
identified in 20-25%. Liver scanning is useful if abnormal LFTs, 
hepatomegaly or significant weight loss suggestive of hepatic metastases 
are present. A routine screening mammogram and a positive screening 
mammogram are shown below (Figures 7 & 8). Ultrasound of a palpable 
mass and ultrasound guided biopsy are also shown below (Figures 9 & 
Video 1). MRI may be helpful in complicated cases (Figure 10). It is 
important to remember that mammograms are screening tools. They have 
limitations. For example, Figure 11a demonstrates a dense breast that 
masks the presence of an adenocarcinoma. This mass was better 
identified by CT, Figure 11b. 
 
 
Figure 7 a,b. Screening Mammogram. Standard mammographic views are the 
following (a) Craniocaudal (CC) View and (b) Mediolateral Oblique (MLO) View. 
University of Massachusetts Medical School, Department of Radiology. 
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Figure 8 a,b. Positive Screening Mammogram. The green arrow points to a 
spiculated mass, biopsy proven invasive ductal carcinoma, in the upper inner 
posterior breast (a) MLO view and (b) compression CC view. University of 
Massachusetts Medical School, Department of Radiology. 
 
 
Figure 9 a,b. Ultrasound of a Palpable Mass. (a) Irregular hypoechoic shadowing 
right breast mass on ultrasound. (b) Yellow arrows indicate the poorly defined 
margins. University of Massachusetts Medical School, Department of Radiology. 
 
 
 
Video 1. Ultrasound Guided Biopsy. University of Massachusetts Medical School, 
Department of Radiology. 
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Figure 10 a,b,c,d. Contrast Enhanced MRI of the Breast. The green arrow points 
to an enhancing mass in the lower outer left breast on subtraction (a) and MIP 
images (b). The mass demonstrates mixed kinetics (c & d). The kinetic curve (d) 
shows initial rapid uptake of contrast from 0 to 173% and progressive washout of 
contrast over time. This pattern of contrast uptake and washout statistically favors 
a malignancy. University of Massachusetts Medical School, Department of 
Radiology. 
 
 
Figure 11 a,b. (a) Standard MLO View. (b) Breast CT of the same patient. Green 
arrow points to a biopsy proven adenocarcinoma that is obscured by normal 
glandular tissue on the routine mammogram. Breast CT was recently approved by 
the FDA with specific restrictions for use only as a diagnostic imaging tool. This 
modality does not have FDA approval for screening at this time but it offers exciting 
avenues of approach in the fight against breast cancer. Images contributed by Drs. 
Andrew Karellas and Srinivasan Vedantham, University of Massachusetts Medical 
School, Department of Radiology, from research supported in part by NCI grant, 
1R21 CA134128-01A2. 
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Stage information for Breast Cancer can be found in the AJCC Staging 
manual and at the NCI- Breast Cancer Treatment (PDQ).2. Figures 12-16 
are three-dimensional staging images of breast cancer. 
 
 
Figure 12. Breast Cancer, T2. University of Massachusetts Medical School, 
Department of Radiation Oncology. 
 
 
Figure 13. Breast Cancer, T2N1 Solitary axillary node. University of 
Massachusetts Medical School, Department of Radiation Oncology. 
 
 
 
 
 
 
Figure 14. Breast Cancer, T2N2, Matted axillary nodes. University  
of Massachusetts Medical School, Department of Radiation Oncology. 
 
 
Figure 15. Breast Cancer, T2N3, Axillary & internal mammary nodes. University of 
Massachusetts Medical School, Department of Radiation Oncology. 
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Figure 16. Breast Cancer, T4dN3. Inflammatory carcinoma, axillary & internal 
mammary nodes. University of Massachusetts Medical School, Department of 
Radiation Oncology. 
 
Oncologists have long used simple drawings of the body to draw diagrams 
of the extent of a patient’s disease. These drawings, referred to as staging 
diagrams, are useful tools to demonstrate extent of disease and facilitate 
treatment planning by clarifying the thought process. The process of filling 
out staging diagrams is a good way to learn staging systems. Interactive 
staging diagrams for breast cancer are available here. 
 
Prognostic Factors 
Poor prognostic factors include higher stage (larger tumor sizes and nodal 
involvement), higher grade, lymphatic vessel invasion (LVI), age < 40, 
negative estrogen receptor/progesterone receptor (ER/PR) status, and 
overexpression of human epidermal growth factor receptor 2 (HER2). 
Figure 17 a & b demonstrate immunohistochemical (IHC) stains for ER 
and PR. 
HER2/neu is a transmembrane tyrosine kinase receptor on chromosome 
17q12. Amplification of HER2 is associated with poor prognosis, early 
relapse, and shorter disease-free survival, therefore accurate detection is 
necessary for treatment. Figure 18 is an example of IHC staining for 
HER2/neu. This is a screening study, since a majority of cases of breast 
cancer cases scoring HER2 weak positive (2+) are not actually Her2/neu 
positive. This study requires confirmation by fluorescence in‐situ 
hybridisation (FISH). Figure 19 a & b show FISH test results for normal 
breast cells (Figure 19a) and HER2/neu+ cells (Figure 19b). 
 
 
Figure 17 a,b. Immunohistochemical Stains for the Estrogen and Progesterone 
Receptor. For either stain, cells are positive if there is nuclear staining. A 
standardized pathology report will also include the percentage of positive cells. (a) 
Low power magnification of ER stain (b) High power of PR stain. University of 
Massachusetts Medical School, Department of Pathology. 
 
 
Figure 18. Immunohistochemical Staining for HER2/neu. In contrast to ER/PR 
staining, Her2/neu is a membranous stain. There are strict guidelines which require 
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circumferential and strong membranous staining of most cells for a positive 
interpretation. Any equivocal cases are triaged for fluorescent in-situ hybridization 
(see next figure). University of Massachusetts Medical School, Department of 
Pathology. 
 
 
Figure 19 a,b. FISH of Invasive Breast Ductal Adenocarcinoma. (a) Normal cell: 
The green signals indicate 2 copies of chromosome 17 and the two red signals are 
HER2. (b) Breast ductal carcinoma cell with multiple HER2 signals that 
proportionally exceed the number of chromosome 17 signals, indicates 
amplification of HER2/neu and can be interpreted as a positive HER2/neu test. 
University of Massachusetts Medical School, Department of Pathology. 
 
Principles of Treatment 
Treatment is multidisciplinary and requires close cooperation between 
surgeons, radiation oncologists and medical oncologists. Patients also 
meet with behavioral medicine, and if indicated, plastic surgeons and 
genetic counselors. Each patient’s individual care is discussed at the 
Multidisciplinary Breast Cancer Tumor Board, at which time the 
radiologists and pathologists review the imaging and pathology and a 
management plan is decided. 
Treatment for invasive cancers begins with accurately staging the patient. 
If metastatic disease is present, systemic therapy becomes the mainstay 
of treatment. For M0 patients, local therapy and sequencing of therapy 
hinge on operability. Locally advanced breast cancers are best served with 
preoperative chemotherapy (usually referred to as neoadjuvant 
chemotherapy). For early stage disease, stages I and II, surgery is 
generally employed first, and the choice is between modified radical 
mastectomy or breast preserving surgery or lumpectomy plus radiation 
therapy (RT). Six randomized prospective trials comparing mastectomy to 
breast preserving surgery plus RT have shown that survival is identical 
between these two choices. Trials have also shown that local failure in the 
breast is markedly reduced by the addition of radiation therapy over 
lumpectomy alone. Adjuvant chemotherapy and/or endocrine therapy can 
further improve local control and also adds a significant survival 
advantage. 
In making the choice between mastectomy and breast preservation with 
RT, several factors are important. It helps if the patient can be easily 
followed for early recurrence detection – e.g. films are easy to read and 
the lesion was readily palpable. Relative contraindications to breast 
preservation plus RT include pregnancy, multicentric disease, diffuse 
malignant calcifications throughout the breast, collagen vascular disease, 
prior RT or persistently positive margins. 
Surgery 
Surgery is important in establishing diagnosis and removing gross 
disease. For DCIS, surgery is typically confined to the breast and options 
include lumpectomy or mastectomy. For invasive disease it becomes 
important to sample the axilla. If the axilla is clinically negative the patient 
is a candidate for sentinel lymph node sampling (SNB). If the axilla is 
involved with tumor then an axillary dissection can be important to both 
determine the exact number of involved nodes and for local control of the 
axilla. A current, ongoing research focus concerns the treatment of low 
volume, clinically occult axillary disease. A recent randomized trial has 
shown no difference in survival in patients who had a sentinel node biopsy 
with no further axillary dissection compared with patients who had an 
axillary dissection in addition to a sentinel node biopsy, regardless of 
whether the sentinel node was involved with cancer.3 This trial was limited 
to patients with smaller tumors, clinically uninvolved nodes and all patients 
received whole breast RT which a subsequent analysis of the RT data 
demonstrated included axillary RT in a high proportion of patients.4 
Another recently published trial randomized patients with clinical N0 
disease found on SNB to have one or two cancer containing nodes to 
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axillary radiotherapy or node dissection and found that while both arms 
provided excellent and statistically identical axillary control, morbidity was 
higher in the dissection arm.5. These trials support that axillary 
radiotherapy may be a utilized instead of axillary dissection for low volume 
sentinel node biopsy detected disease. 
Radiation Therapy (RT) 
RT after surgery kills any cancer cells that could remain in the breast, the 
chest wall, or nodal basins. RT for early stage disease can allow for breast 
preserving surgery instead of mastectomy. In Phase III breast trials for 
DCIS, moderate dose RT has been shown to eradicate residual 
microscopic disease in the breast. This reduces the chance that the 
cancer will come back, thus allowing patients the ability to conserve the 
breast. Likewise, Phase III trials for stage I-II breast cancer have proven 
that adding RT to lumpectomy dramatically reduces breast cancer 
recurrence in the breast over lumpectomy alone, and that survival is 
identical between mastectomy and lumpectomy plus RT. Post-mastectomy 
RT (PMRT) is indicated for stage III disease (high risk patients with 
cancers > 5 cm or involving lymph nodes). RT is also used for recurrent 
breast cancer and in stage IV disease to palliate symptomatic sites. 
The most common way RT is delivered is via external beam using either 
photons or electrons. A typical curative course lasts 6 weeks, with daily 
treatments delivered Monday- Friday, and about 15 minutes is required 
per treatment. Ongoing trials are assessing the value of shorter course 
partial breast irradiation. In the palliative setting, RT can be delivered in a 
much shorter course, typically over 2 weeks. 
RT is carefully planned and delivered. Treatment planning CT scans with 
either 3D or IMRT treatment planning allow precise targeting and minimize 
dose to adjacent normal structures. Common side effects of RT include 
temporary fatigue and skin changes that mimic sunburn. 
Chemotherapy 
Many randomized trials, dating back over four decades and involving tens 
of thousands of women have definitively shown that post-operative 
(adjuvant) chemotherapy or hormonal therapy can prevent breast cancer 
recurrence and lower the risk of dying from breast cancer in women with 
completely resected Stage I-III disease. The Early Breast Cancer Trialists 
Collaborative Group (EBCTCG) publishes a large overview and meta-
analysis of drug treatment of early stage breast cancer about every five 
years. The most recent update6 showed that post-operative chemotherapy 
lowers the risk of dying from recurrent breast cancer by 38% in women 
younger than 50 and by 20% in women older than 50. In women with 
estrogen receptor positive tumors, tamoxifen lowers the risk of death by 
31%. 
The EBCTCG meta-analyses have helped standardize treatments of 
patients with early stage breast cancer. However, these analyses may lag 
behind state-of-the-art treatments. In the last decade, several trials have 
demonstrated that women with cancers that over-express her-2 derive 
additional benefit from treatment with the monoclonal antibody 
trastuzumab. 
These studies show that the addition of trastuzumab to standard 
chemotherapy in the treatment of patients with her-2 positive disease 
lowers the risk of death from recurrent breast cancer by an additional 33% 
compared with treatment with chemotherapy alone. 
At present, it is standard of care to recommend tamoxifen to any 
premenopausal woman with an estrogen receptor positive tumor.  
Postmenopausal women with estrogen receptor positive tumors can also 
receive tamoxifen, though aromatase inhibitors are more effective than 
tamoxifen and are largely replacing tamoxifen in this group of women. 
Chemotherapy will usually be recommended to women with estrogen 
receptor negative disease, or to patients with lymph nodes involved by 
tumor, regardless of estrogen receptor status. 
Because many patients with early stage breast cancer are cured by 
surgery alone and because chemotherapy can cause significant side 
effects, efforts are made to try to define those patients most likely to 
benefit from chemotherapy. Increasingly, gene expression assays are 
used to assess tumor tissue both for likelihood of developing recurrent 
cancer as well as for the probability of benefiting from chemotherapy. It is 
likely that such assays will become a common component of the overall 
evaluation of breast cancer patients to help guide treatment 
decisions.7.Some useful websites include: www.adjuvantonline.com, and 
www.nccn.org. 
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Treatment for Locally Advanced Breast Cancer 
At the time of diagnosis, 2% to 5% of all breast cancer are locally 
advanced. This includes inflammatory breast cancer (T4d) which on 
clinical exam presents as diffuse erythema, warmth, edema (peau d' 
orange), induration, + palpable mass. The hallmark of inflammatory breast 
cancer on skin biopsy is dermal lymphatic invasion.  Treatment generally 
consists of induction chemotherapy and, if good response, mastectomy 
followed by post-mastectomy radiation therapy. If there is only a partial 
response to chemotherapy with residual skin disease remaining, then 
radiation therapy followed by mastectomy is employed. This is followed by 
adjuvant chemotherapy and/or hormonal therapy if indicated. 
 
Treatment for Metastatic Breast Cancer 
Approximately 40,000 U.S. patients will die of metastatic breast cancer 
each year. Metastatic breast cancer is incurable, with a median survival of 
only 2 to 3 years. With newer systemic treatments, perhaps 5 to 10% will 
live > 10 years, especially those who achieve a complete remission (CR). 
Predicting for a good response to therapy include good performance 
status, younger age, and lower tumor burden. Additionally, the natural 
history of metastatic breast cancer is affected by the initial site of relapse. 
Patients who relapse initially on their chest wall or in regional lymph nodes 
typically have a longer life span than patients whose initial relapse is in 
bones or the lungs. Patients who present with metastatic disease in the 
liver or brain tend to have a poor prognosis. Imaging modalities used in the 
diagnosis and monitoring of metastatic disease include PET/CT (Figure 20 
a & b) and bone scan (Figure 21a). CT (Figure 21b) is also useful for 
identification of breast cancer bony metastases as CT has higher 
resolution, and may aid in assessment of bone integrity and risk for 
pathologic fracture. 
 
 
 
 
Figure 20 a,b. PET/CT. (a) CT has high spatial resolution for identification of 
anatomic structures while (b) PET shows areas of increased metabolic activity. 
Long arrow points to an invasive ductal carcinoma in the right lateral breast. Short 
arrow points to metastatic disease to the axillary lymph nodes. University of 
Massachusetts Medical School, Department of Radiology. 
 
 
Figure 21 a,b. (a) Bone scan shows heterogeneous radiotracer uptake along the 
medial proximal left femur. (b) CT aids with higher spatial resolution showing lytic 
breast metastasis to the proximal left femur and lower lumber spine. University of 
Massachusetts Medical School, Department of Radiology. 
 
Conclusion 
Management of breast cancer requires a true multidisciplinary 
management team. As the science develops, both detection techniques 
and treatment are evolving rapidly. Over the last century, the mortality rate 
and the late morbidity of treatment and uncontrolled disease have declined 
dramatically. Hopefully future advances will continue to improve both 
morbidity and mortality. 
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Thought Questions 
1. Why should patients with early stage (Stages I-III) breast cancer who 
have a complete resection of their cancer be at risk of relapse? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. If metastatic breast cancer is incurable, why should chemotherapy or 
hormonal blockade be able to improve survival in early stage disease? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
Expert Answer: 
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3. Survival is identical in patients with early stage disease who are 
treated with either mastectomy or lumpectomy followed by radiation. 
Yet there is a risk (<10%) of recurrent breast cancer in the residual 
breast after radiation. Why would survival in patients who have 
lumpectomy and radiation be identical to that seen in patients who 
have mastectomy despite the risk of recurrence in the residual breast? 
Your answer: 
 
 
 
 
 
 
 
 
 
Expert Answer: 
 
 
 
 
 
 
 
 
 
 
 
 
Glossary 
Adjuvant chemotherapy- Chemotherapy given prior to surgical resection of 
tumor 
Lumpectomy- Surgical procedure to remove breast tumor and a small 
margin surrounding it 
Mastectomy- Total surgical removal of a breast 
Neoadjuvant chemotherapy- Chemotherapy given prior to surgical 
resection of tumor 
Nulliparity– The state of never having given birth. Often used 
(inaccurately) to imply never having been pregnant 
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Staging Diagrams 
 
AJCC staging consists of the disease (cancer site/type), the type of staging or timing of the 
staging: clinical (c) versus pathologic (p) versus post-neoadjuvant therapy (yp), the stage group 
(I-IV) and the T (primary site), N (nodal involvement), and M (metastasis) stage categories.  
Oncologists draw tumor deposits on outlines of body regions, usually with red ink, during the 
staging of a cancer. The process of drawing helps physicians remember the patient’s stage; 
drawing a series of stages for a given disease site helps learn the staging system, and makes 
the AJCC staging table meaningful for visual learners. 
In this packet are: 
1. Blank staging diagrams to assist with staging the patients you see. Printing out these 
blank diagrams and staging patients on the diagrams would be a valuable exercise. 
2. Case-based interactive staging diagrams to provide a self-assessment of your staging 
knowledge. A patient’s extent of disease is described in each case. Write the Type of 
Staging, Stage Group, T stage, N stage, and M stage in the corresponding blank fields. 
Clicking on the Expert Answers and Diagrams link will trigger the correct stage and 
annotated diagram to appear. 
The blank diagrams below were created using a CT image set on the Varian Aria Radiation 
Therapy Treatment Planning System. Images Courtesy of University of Massachusetts Medical 
School, Department of Radiation Oncology. 
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Blank Staging Diagram Form for Breast Cancer 
 
AJCC Breast Cancer Staging, 7th Edition is available at: 
https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf 
 
Disease: Breast Cancer 
Type of Staging  Stage  T  N  M  
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Interactive Staging Diagram Form for Breast Cancer 
 
AJCC Breast Cancer Staging, 7th Edition is available at: 
https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf 
 
A. Patient presents with a 2.5 cm mass in the upper outer quadrant of the left breast. Initial 
physical examination is remarkable for a single, 2x1 cm rock-hard, non-tender, mobile mass in 
left axilla, consistent with involved lymph node. Patient is otherwise asymptomatic. Needle 
biopsy of palpable breast mass is positive for ductal carcinoma cells. 
Disease: Breast Cancer 
Type of Staging  Stage  T  N  M  
 
 
 
 
 
 
 
  
Click here to reveal 
Expert Answers and 
Annotated Diagram 
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B. Patient presents with an ulcerated, fungating, foul smelling mass replacing her right 
breast, and a palpable node in the right supraclavicular fossa. She is otherwise asymptomatic, 
but has been hiding from her family for many months and has not seen a physician since the 
birth of her last child 40 years ago. Biopsy reveals grade 1 infiltrating ductal carcinoma in breast. 
Disease: Breast Cancer 
Type of Staging  Stage  T  N  M  
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Annotated Diagram 
 
19 
  31 July 2015 
 
C. On routine mammography, a few very suspicious calcifications are seen in the lower 
inner quadrant of the right breast of a 40 year old, asymptomatic nurse. Physical examination is 
entirely unremarkable. Needle biopsy is not diagnostic, so lumpectomy is performed. Pathology 
is read as ductal carcinoma-in-situ, with necrosis and high nuclear grade. 
Disease: Breast Cancer 
Type of Staging  Stage  T  N  M  
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D. A 60 year old woman comes to see her primary because she bumped her left breast 
several weeks ago and she felt a small mass under the bruise in the upper inner quadrant. It 
measures about 1.5 cm, and the rest of the physical examination is normal. Needle biopsy is 
positive, and lumpectomy and sentinel node procedure is performed. Pathology comes back 1.5 
cm invasive ductal carcinoma with 0.4 cm cluster of malignant cells in the sentinel node. 
Disease: Breast Cancer 
Type of Staging  Stage  T  N  M  
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E. On routine annual physical examination, a 50 year old woman is found to have a 6 cm 
mass deep in the central right breast, with a 5 cm firm, fixed, mass in the right axilla. She feels 
fine, and never noticed anything unusual. Biopsy reveals grade 3 infiltrating ductal carcinoma in 
the axillary mass. 
Disease: Breast Cancer 
Type of Staging  Stage  T  N  M  
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F. On routine annual physical examination, a 50 year old woman is found to have a 6 cm 
mass deep in the central right breast, with a 5 cm firm, fixed, mass in the right axilla. She feels 
fine, and never noticed anything unusual. Biopsy reveals grade 3 infiltrating ductal carcinoma in 
the axillary mass. 
The patient receives 3 cycles of chemotherapy, and the tumor now measures about 2 cm and 
the axillary mass is no longer palpable. Lumpectomy and sentinel node procedure is performed 
and pathology reveals a 0.9 cm mass in the central breast specimen and 12 negative lymph 
nodes. 
Disease: Breast Cancer 
Type of Staging  Stage  T  N  M  
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G. 10 years ago, a patient, now 79, underwent a 
mastectomy for high grade ductal carcinoma in the right 
breast, the tumor measured 4 cm in greatest diameter, the 
ipsilateral internal mammary node was seen on preoperative 
MRI and so removed and was positive.  
On follow-up now, she complains of back and left shoulder 
pain, constant, waking her from sleep and morning headache 
with nausea. MRI of spine reveals tumor in the fourth thoracic 
vertebra, and bone scan is positive in many areas, including 
multiple vertebrae and the left proximal humerus. MRI of brain 
shows an enhancing lesion consistent with metastasis. CT 
chest demonstrates left lung metastasis and a liver lesion. 
Disease: Breast Cancer 
Type of Staging  __   Stage: ____    T  _    N  _     M  __ 
 
Click here to reveal Expert Answers and Annotated Diagram 
 
 
 
 
 
